FREMONT, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a
clinical-stage biopharmaceutical company, today announced the appointment of Linda Grais, M.D., J.D. to its board of directors.
Dr. Grais brings a diverse and important set of experience and expertise to Zosano. After graduation from Yale Medical School
and residency at UCSF, she was an assistant professor at UCSF in internal medicine, received her J.D. from Stanford Law School
where she was an editor of Stanford Law and Policy Review before joining Wilson Sonsini Goodrich & Rosati as an associate
representing Life Science companies. Dr. Grais then founded Structural GenomiX Inc, which was sold to Eli Lilly & Co. in 2008 and
became a partner at InterWest Partners, a venture capital firm, investing in biotechnology and medical device companies. Dr. Grais
became the President and CEO of Ocera Therapeutics, Inc. in 2012 and successfully led Ocera through the acquisition by Mallinckrodt
in 2017. She currently serves on the Board of Directors of Arca Biopharma (NASDAQ: ABIO) and PRA Health Sciences (NASDAQ:
PRAH).
“Linda brings a unique combination of expertise to Zosano Pharma,” commented John Walker Chairman and CEO. "Her experience in
clinical medicine, drug development, corporate transactions and managing complex strategic issues will serve us well as we continue
to development our drug delivery technology and expand our clinical portfolio.”
“I am very pleased to join the Board of Zosano Pharma at this exciting time for the company. With the projected filing of the
company’s first NDA in the fourth quarter, expansion of the clinical portfolio in new therapeutic areas and the continued
development of Zosano’s drug delivery platform for biological agents, there is much to accomplish, and much that I hope to
contribute,” said Dr. Grais.
About Qtrypta (M207)
Qtrypta is Zosano’s lead program and is a proprietary formulation of zolmitriptan delivered utilizing its proprietary ADAM
technology. Zosano's ADAM technology consists of titanium microneedles coated with drug, and in the case of Qtrypta, its
formulation of zolmitriptan. The drug-coated microneedles penetrate into the epidermis and dermis, where the investigational drug
is dissolved and enters into the bloodstream. In February 2017, the Company announced statistically significant results from the
ZOTRIP pivotal study, in which the 3.8mg dose of Qtrypta met both co-primary endpoints, achieving pain freedom and most bothersome
symptom freedom at 2 hours. In November 2017, the Company announced the initiation of its long-term safety study evaluating Qtrypta
and expects to file an NDA for Qtrypta in the fourth quarter of 2019.
Forward-Looking Statements
This press release contains forward-looking statements regarding the expected timing of an NDA for Qtrypta and other future
events and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should,"
"might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast,"
"designed," "goal," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking.
These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially.
These include, without limitation, risks and uncertainties associated with the process of discovering, developing and
commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a
business around such products and other risks and uncertainties described under the heading "Risk Factors" in the Company's most
recent quarterly report on Form 10-Q. Although Zosano believes that the expectations reflected in these forward-looking statements
are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances
reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information
currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.
Zosano Contact:
Greg Kitchener
Chief Financial Officer
510-745-1200
Media Contact:
Sara Zelkovic
LifeSci Public Relations
sara@lifescipublicrelations.com
646-876-4933
